You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 8, 2024

Investigational Drug Information for Netupitant


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Netupitant?

Netupitant is an investigational drug.

There have been 18 clinical trials for Netupitant. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2021.

The most common disease conditions in clinical trials are Vomiting, Nausea, and Breast Neoplasms. The leading clinical trial sponsors are Helsinn Healthcare SA, National Cancer Institute (NCI), and Consorzio Oncotech.

There are ninety US patents protecting this investigational drug and eight hundred and eighty-three international patents.

Recent Clinical Trials for Netupitant
TitleSponsorPhase
Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell CarcinomaSichuan Cancer Hospital and Research InstituteN/A
Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCCGuangxi Medical UniversityPhase 3
Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)Helsinn Healthcare SAPhase 4

See all Netupitant clinical trials

Clinical Trial Summary for Netupitant

Top disease conditions for Netupitant
Top clinical trial sponsors for Netupitant

See all Netupitant clinical trials

US Patents for Netupitant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Netupitant ⤷  Sign Up Crystalline forms of fosnetupitant Helsinn Healthcare SA (Lugano/Pazzallo, CH) ⤷  Sign Up
Netupitant ⤷  Sign Up Cyclohexyl pyridine derivative KISSEI PHARMACEUTICAL CO., LTD. (Matsumoto, Nagano, JP) ⤷  Sign Up
Netupitant ⤷  Sign Up Method for cancer cell reprogramming STC.UNM (Albuquerque, NM) ⤷  Sign Up
Netupitant ⤷  Sign Up Estrogen-related receptor alpha based protac compounds and associated methods of use Yale University (New Haven, CT) Arvinas, Inc. (New Haven, CT) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Netupitant

Drugname Country Document Number Estimated Expiration Related US Patent
Netupitant Australia AU2016335060 2035-10-06 ⤷  Sign Up
Netupitant Canada CA2996466 2035-10-06 ⤷  Sign Up
Netupitant China CN108137626 2035-10-06 ⤷  Sign Up
Netupitant European Patent Office EP3359547 2035-10-06 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.